Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California. Show more

2200 Bridge Pkwy, Redwood City, CA, 94065, United States

Biotechnology

Healthcare

Market Cap

22.91M

52 Wk Range

$0.62 - $7.19

Previous Close

$0.82

Open

$0.82

Volume

63,895

Day Range

$0.82 - $0.87

Enterprise Value

9.842M

Cash

14.14M

Avg Qtr Burn

-14.55M

Insider Ownership

1.19%

Institutional Own.

60.57%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Briquilimab (SC) Details Chronic spontaneous urticaria (CSU)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SC) Details Cold urticaria (ColdU) or symptomatic dermographism (SD)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SA SC) Details Asthma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab Details Severe combined immunodeficiency due to complete RAG1/2 deficiency	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.